Parasuraman Subramani, Zhen Khor Ming, Banik Urmila, Christapher Parayil Varghese
Unit of Pharmacology, Faculty of Pharmacy, AIMST University, Kedah, Malaysia.
Department of Pathology, Faculty of Medicine, AIMST University, Kedah, Malaysia.
Pharmacognosy Res. 2017 Jul-Sep;9(3):247-252. doi: 10.4103/pr.pr_8_17.
To evaluate the effect of curcumin on olanzapine-induced obesity in rats.
Sprague-Dawley (SD) rats were used for experiments. The animals were divided into six groups, namely, normal control, olanzapine control, betahistine (10 mg/kg), and curcumin 50, 100, and 200 mg/kg treated groups. Except the normal control group, all other animals were administered with olanzapine 4 mg/kg intraperitoneally to induce obesity. The drugs were administered once daily, per oral for 28 days. During the experiment, body weight changes and behavior alterations were monitored at regular intervals. At the end of the experiment, blood sample was collected from all the experimental animals for biochemical analysis. Part of the liver and kidney tissues was harvested from the sacrificed animals and preserved in neutral formalin for histopathological studies.
Curcumin showed a significant reduction in olanzapine-induced body weight gain on the rats and improved the locomotor effects. The effect of curcumin on olanzapine-induced body weight gain is not comparable with that of betahistine.
This study has shown metabolic alteration effect of curcumin on olanzapine, an antipsychotic drug, treated SD rats.
Olanzapine is an atypical antipsychotic drug used for the treatment of schizophrenia and bipolar disorder. Obesity is an adverse effect of olanzapine, and the present study was made an attempt to study the effect of curcumin on olanzapine-induced obesity in rats. In this present study, curcumin significantly reduced olanzapine-induced body weight gain in rats. : 5HT: 5-hydroxytryptamine, ALP: Alkaline phosphatase, ALT: Alanine transaminase, ANOVA: Analysis of variance, AST: Aspartate transaminase, CMC: Carboxymethyl cellulose, D: Dopamine, H and E: Hematoxylin and Eosin stain, H: Histamine, HDL-C: Highdensity lipoprotein cholesterol, IP: Intraperitoneal, MAO: Monoamine oxidase, NaOH: Sodium hydroxide, SD rats: Sprague Dawley rats, TCs: Total cholesterols, TG: Triglyceride.
评估姜黄素对奥氮平诱导的大鼠肥胖的影响。
采用斯普拉格-道利（SD）大鼠进行实验。将动物分为六组，即正常对照组、奥氮平对照组、倍他司汀（10 mg/kg）组以及姜黄素50、100和200 mg/kg治疗组。除正常对照组外，所有其他动物均腹腔注射4 mg/kg奥氮平以诱导肥胖。药物每日口服给药一次，持续28天。实验期间，定期监测体重变化和行为改变。实验结束时，采集所有实验动物的血液样本进行生化分析。从处死后的动物身上采集部分肝脏和肾脏组织，保存在中性福尔马林中用于组织病理学研究。
姜黄素显著降低了奥氮平诱导的大鼠体重增加，并改善了运动效应。姜黄素对奥氮平诱导的体重增加的作用与倍他司汀不可比。
本研究表明姜黄素对使用抗精神病药物奥氮平治疗的SD大鼠有代谢改变作用。
奥氮平是一种用于治疗精神分裂症和双相情感障碍的非典型抗精神病药物。肥胖是奥氮平的一种不良反应，本研究试图研究姜黄素对奥氮平诱导的大鼠肥胖的影响。在本研究中，姜黄素显著降低了奥氮平诱导的大鼠体重增加。：5HT：5-羟色胺，ALP：碱性磷酸酶，ALT：丙氨酸转氨酶，ANOVA：方差分析，AST：天冬氨酸转氨酶，CMC：羧甲基纤维素，D：多巴胺，H和E：苏木精和伊红染色，H：组胺，HDL-C：高密度脂蛋白胆固醇，IP：腹腔内，MAO：单胺氧化酶，NaOH：氢氧化钠，SD大鼠：斯普拉格-道利大鼠，TCs：总胆固醇，TG：甘油三酯。
